Lineage Cell Therapeutics, Inc. Contract with Customer, Receivable, after Allowance for Credit Loss, Current
Lineage Cell Therapeutics, Inc. (LCTX) had Contract with Customer, Receivable, after Allowance for Credit Loss, Current of $325.00 thousand as of 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Notes
us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent · last filed 2023-11-09
- 2023-09-30: Contract with Customer, Receivable, after Allowance for Credit Loss, Current $325.00K.
- 2022-12-31: Contract with Customer, Receivable, after Allowance for Credit Loss, Current $297.00K.
| Period end | Contract with Customer, Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2023-09-30 | $325.00K 10-Q · filed 2023-11-09 |
| 2022-12-31 | $297.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |